Combination of epigallocatechin-3-gallate and cerubidin and use thereof

A technology of epigallocatechin and gallate, which is applied in the fields of medicine and genetic engineering, can solve the problems of no combination of EGCG and DNR, and achieve the effect of enhancing anti-tumor effect, reducing cardiotoxicity and enriching resources

Inactive Publication Date: 2009-08-19
FUDAN UNIV
View PDF1 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] So far, there are no reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of epigallocatechin-3-gallate and cerubidin and use thereof
  • Combination of epigallocatechin-3-gallate and cerubidin and use thereof
  • Combination of epigallocatechin-3-gallate and cerubidin and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1 Synergism of EGCG on DNR Inhibiting Tumor Cell Proliferation

[0054] The MTT method was used to detect the effect of EGCG on the effect of DNR on inhibiting the proliferation of tumor cells. The selected concentration of EGCG (20 μM), under this concentration, EGCG hardly affects the growth of selected tumor cells when used alone. After 0.4μM DNR acted on HepG2 for 48 hours, the number of cell survival was 49.3% of that of the control cells without drug addition. When used in combination with 10μM and 20μM EGCG, the number of cell survival decreased to 40% and 33.2%. Compared with DNR acting alone, EGCG combined with DNR increased the inhibition of cell proliferation by 16%, and the synergistic effect was significant, and the synergistic effect had an EGCG concentration gradient effect ( figure 1 ). In SMMC7721, EGCG showed a similar synergistic effect. After DNR combined with 20 μM EGCG, the cell survival was reduced from 65.9% to 45.3%, and the inhibitor...

Embodiment 2

[0055] Example 2 EGCG enhances the effect of DNR on G2 / M arrest of tumor cells

[0056] The effect of EGCG on DNR-induced cell cycle arrest in G2 / M phase was further detected. HepG2 and SMMC7721 cells were also selected. 24 hours after HepG2 was treated with 0.03 and 0.04 μM DNR, compared with the control cells without drug, the cells in G2 / M phase increased from 8.37% to 35.9% and 52.6%, respectively, and a significant G2 / M phase cycle arrest occurred , and there is a concentration-dependence of DNR, the higher the concentration, the more cells in G2 / M phase. 10μM EGCG had no significant effect on the cell cycle, when the same concentration of EGCG was combined with 0.03μM DNR, the number of cells in G2 / M phase increased from 35.9% to 41.28%; when EGCG was combined with 0.04μM DNR, the number of cells in G2 / M phase increased from 52.6% to 61.55%. EGCG can enhance the effect of DNR on cell G2 / M phase arrest.

[0057] The results of SMMC7721 were also similar. When EGCG was...

Embodiment 3

[0059] Example 3 Effect of EGCG on the anti-tumor activity of DNR in Hep3B expressing exogenous CBR1

[0060] First, western blot was used to detect the expression of CBR1 in the stable strain, and the cell lysate was detected by anti-CBR1 antibody and anti-Myc antibody. Hep3B-CBR1 had both endogenous CBR1 expression and exogenous CBR1-Myc expression. Hep3B-pcDNA3 .1 Expression of only endogenous CBR1. Use β-actin to level the loading amount ( image 3 ). The results proved that Hep3B-CBR1 had higher expression of CBR1.

[0061] Next, the effect of overexpression of CBR1 on cell drug resistance was detected. Cell survival was detected by MTT as an indicator of cell resistance to the drug. Drugs treated the control group Hep3B-pcDNA3.1 and Hep3B-CBR1 under the same conditions, that is, with 0.4μM DNR for 48 hours, compared with Hep3B-pcDNA3.1, the survival of Hep3B-CBR1 cells increased from 34.4% to 52.8% respectively , similarly, the survival of Hep3B-CBR1 cells increased...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine and gene engineering, and provides a composition for inhibiting the proliferation of tumor cells. The composition contains epigallocatechin gallate (EGCG) and daunorubicin (DNR), and the mass ratio of the epigallocatechin gallate to the daunorubicin is 600: 1-1: 2. The combination of the EGCG and the DNR, on one hand, ensures that the effect of inhibiting the proliferation of the tumor cells is more obvious than the superposition of single use effects, on the other hand, the combination of the EGCG and the DNR obviously reduces the using amount of the DNR, greatly reduces the cardiac toxicity of the DNR, and strengthens the anti-tumor effect of the DNR at the same time. The EGCG is a natural tea extract, has rich resource and low price, and almost has no toxic side effect after more than one thousand years of drinking, so the combination of the EGCG and the DNR relatively reduces the using amount of the DNR and drug cost. The invention provides a high-efficiency cheap anti-tumor pharmaceutical composition, which improves the inhibition rate of tumor and reduces the treatment cost of tumor patients at the same time.

Description

technical field [0001] The invention belongs to the fields of medicine and genetic engineering, and relates to a composition of epigallocatechin gallate (EGCG) and daunorubicin (DNR) and an application thereof. Background technique [0002] Anthracyclines are one of the most effective antitumor drugs, including DNR (DNR) and doxorubicin (DOX), which can treat a variety of cancers, including leukemia and solid tumors (Minotti, G., et al., Anthracyclines : molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.Pharmacol Rev, 2004.56(2): p.185-229), has an anthracycline plane, which can be fitted between DNA base pairs and tightly bound to DNA Therefore, the nucleic acid contains a relatively high concentration of drugs. This kind of chimerism can lead to obstacles in the DNA space structure, thereby inhibiting DNA and DNA-dependent RNA synthesis. The impact on RNA is particularly obvious, and it can selectively act on purine nuclei. Glycosi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/353A61P35/00
Inventor 余龙黄维雪丁丽娅
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap